|
Drug company insiders are profiting handsomely from world’s desperate hope for a COVID-19 vaccine
|
|
Insiders at companies developing COVID-19 vaccines and treatments aren’t waiting until they finish the job to collect their reward. Executives, board members, and related investment funds have made fortunes from the rise in their companies' stock prices before a single vaccine has proven safe or a game-changing treatment has been approved.
Since March, these insiders at a dozen companies have sold more than $1.3 billion in stock, up from just $74 million in the same period last year, according to information compiled by Equilar, a data provider based in Redwood City, Calif., and analyzed by the Globe.
Read the full story at BostonGlobe.com.
|
|
|
|
|
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list.
|
|
|
|
